BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 28587761)

  • 1. ITV, mid-ventilation, gating or couch tracking - A comparison of respiratory motion-management techniques based on 4D dose calculations.
    Ehrbar S; Jöhl A; Tartas A; Stark LS; Riesterer O; Klöck S; Guckenberger M; Tanadini-Lang S
    Radiother Oncol; 2017 Jul; 124(1):80-88. PubMed ID: 28587761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Respiratory motion-management in stereotactic body radiation therapy for lung cancer - A dosimetric comparison in an anthropomorphic lung phantom (LuCa).
    Ehrbar S; Perrin R; Peroni M; Bernatowicz K; Parkel T; Pytko I; Klöck S; Guckenberger M; Tanadini-Lang S; Weber DC; Lomax A
    Radiother Oncol; 2016 Nov; 121(2):328-334. PubMed ID: 27817945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ITV versus mid-ventilation for treatment planning in lung SBRT: a comparison of target coverage and PTV adequacy by using in-treatment 4D cone beam CT.
    Bellec J; Arab-Ceschia F; Castelli J; Lafond C; Chajon E
    Radiat Oncol; 2020 Mar; 15(1):54. PubMed ID: 32127010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MLC tracking for lung SABR reduces planning target volumes and dose to organs at risk.
    Caillet V; Keall PJ; Colvill E; Hardcastle N; O'Brien R; Szymura K; Booth JT
    Radiother Oncol; 2017 Jul; 124(1):18-24. PubMed ID: 28655454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-time 4DMRI-based internal target volume definition for moving lung tumors.
    Rabe M; Thieke C; Düsberg M; Neppl S; Gerum S; Reiner M; Nicolay NH; Schlemmer HP; Debus J; Dinkel J; Landry G; Parodi K; Belka C; Kurz C; Kamp F
    Med Phys; 2020 Apr; 47(4):1431-1442. PubMed ID: 31955430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel four-dimensional radiotherapy planning strategy from a tumor-tracking beam's eye view.
    Li G; Cohen P; Xie H; Low D; Li D; Rimner A
    Phys Med Biol; 2012 Nov; 57(22):7579-98. PubMed ID: 23103415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel concept to include uncertainties in the evaluation of stereotactic body radiation therapy after 4D dose accumulation using deformable image registration.
    Azcona JD; Huesa-Berral C; Moreno-Jiménez M; Barbés B; Aristu JJ; Burguete J
    Med Phys; 2019 Oct; 46(10):4346-4355. PubMed ID: 31402461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor control probability and the utility of 4D vs 3D dose calculations for stereotactic body radiotherapy for lung cancer.
    Valdes G; Robinson C; Lee P; Morel D; Low D; Iwamoto KS; Lamb JM
    Med Dosim; 2015; 40(1):64-9. PubMed ID: 25542785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A method for deriving a 4D-interpolated balanced planning target for mobile tumor radiotherapy.
    Roland T; Hales R; McNutt T; Wong J; Simari P; Tryggestad E
    Med Phys; 2012 Jan; 39(1):195-205. PubMed ID: 22225288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-time 4D dose reconstruction for tracked dynamic MLC deliveries for lung SBRT.
    Kamerling CP; Fast MF; Ziegenhein P; Menten MJ; Nill S; Oelfke U
    Med Phys; 2016 Nov; 43(11):6072. PubMed ID: 27806589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-dimensional versus four-dimensional dose calculation for volumetric modulated arc therapy of hypofractionated treatments.
    Ehrbar S; Lang S; Stieb S; Riesterer O; Stark LS; Guckenberger M; Klöck S
    Z Med Phys; 2016 Mar; 26(1):45-53. PubMed ID: 26187810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential dosimetric benefits of adaptive tumor tracking over the internal target volume concept for stereotactic body radiation therapy of pancreatic cancer.
    Karava K; Ehrbar S; Riesterer O; Roesch J; Glatz S; Klöck S; Guckenberger M; Tanadini-Lang S
    Radiat Oncol; 2017 Nov; 12(1):175. PubMed ID: 29121945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosimetric comparison of stereotactic body radiotherapy using 4D CT and multiphase CT images for treatment planning of lung cancer: evaluation of the impact on daily dose coverage.
    Wang L; Hayes S; Paskalev K; Jin L; Buyyounouski MK; Ma CC; Feigenberg S
    Radiother Oncol; 2009 Jun; 91(3):314-24. PubMed ID: 19111362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simulation of dosimetric consequences of 4D-CT-based motion margin estimation for proton radiotherapy using patient tumor motion data.
    Koybasi O; Mishra P; St James S; Lewis JH; Seco J
    Phys Med Biol; 2014 Feb; 59(4):853-67. PubMed ID: 24487573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosimetric Consequences of 3D Versus 4D PET/CT for Target Delineation of Lung Stereotactic Radiotherapy.
    Siva S; Chesson B; Callahan JW; Hardcastle N; Crawford L; Antippa P; Wright G; MacManus MP; Hicks RJ; Kron T; Ball DL
    J Thorac Oncol; 2015 Jul; 10(7):1112-5. PubMed ID: 26134229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose calculations accounting for breathing motion in stereotactic lung radiotherapy based on 4D-CT and the internal target volume.
    Admiraal MA; Schuring D; Hurkmans CW
    Radiother Oncol; 2008 Jan; 86(1):55-60. PubMed ID: 18082905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-adjusted internal target volume: a novel approach focusing on heterogeneity of tumor motion based on 4-dimensional computed tomography imaging for radiation therapy planning of lung cancer.
    Nishibuchi I; Kimura T; Nakashima T; Ochi Y; Takahashi I; Doi Y; Kenjo M; Kaneyasu Y; Ozawa S; Murakami Y; Wadasaki K; Nagata Y
    Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):1129-1137. PubMed ID: 25035218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of the mid-ventilation method for the planning of stereotactic lung plans.
    Thomas SJ; Evans BJ; Harihar L; Chantler HJ; Martin AGR; Harden SV
    Radiother Oncol; 2019 Aug; 137():110-116. PubMed ID: 31085390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Imaging protocols for the management of respiratory motions in the radiotherapy planning for early stage lung cancer patients].
    Pócza T; Pesznyák C; Lövey J; Bajcsay A; Szilágyi A; Almády B; Major T; Polgár C
    Magy Onkol; 2015 Jun; 59(2):133-8. PubMed ID: 26035161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy.
    Shaverdian N; Tenn S; Veruttipong D; Wang J; Hegde J; Lee C; Cao M; Agazaryan N; Steinberg M; Kupelian P; Lee P
    Br J Radiol; 2016; 89(1059):20150963. PubMed ID: 26764282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.